Compare KNDI & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNDI | VTGN |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.8M | 122.1M |
| IPO Year | N/A | N/A |
| Metric | KNDI | VTGN |
|---|---|---|
| Price | $0.85 | $0.72 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | 237.6K | ★ 5.7M |
| Earning Date | 03-13-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $104,035,613.00 | $721,000.00 |
| Revenue This Year | N/A | $54.26 |
| Revenue Next Year | N/A | $478.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $0.68 |
| 52 Week High | $1.81 | $5.14 |
| Indicator | KNDI | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.23 | 22.91 |
| Support Level | $0.86 | $0.68 |
| Resistance Level | $1.11 | $0.84 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | -0.01 | -0.39 |
| Stochastic Oscillator | 13.86 | 1.35 |
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.